探花合集 Pharma Solutions today announced that two of its experts will present at the upcoming BioProcess International Conference & Exhibition (BPI).
Mr. Andrew Sandford, Vice President of Business Development, 探花合集 Biologics will present on Thursday, Sept. 6 at 1:25 p.m. In his presentation, titled 鈥Bringing Biologic Products to Market Faster by Partnering with a Single Services Provider from Development Through Commercial Supply鈥, Mr. Sandford will discuss the advantages of working with a single solutions provider for biologics cell line development through to finished product supply.
With 24 years of experience in business development and marketing, at 探花合集 Mr. Sandford has responsibility for leading the company鈥檚 international business development team. He joined 探花合集 Biologics from Selexis where he was Vice President of Business Development. He had previously held positions at Cambrex鈥檚 Bioproducts and Biopharma segments (now part of Lonza), DOW Chemical, and GE. Mr. Sandford holds a bachelor鈥檚 degree in microbiology from the State University of New York at Plattsburg.
On Friday, Sept. 7 at 11:05 a.m. Victor Vinci, Ph.D., Vice President, Product and Process Development, 探花合集 Biologics will present as part of the 鈥楽peed from Gene to Market鈥 session. In his presentation, titled 鈥Integrated Biologics Development and Manufacturing from Early Phase to Process Performance Qualification (PPQ) and Product Launch鈥, Dr. Vinci will explain how integrated planning of biologics development, validation and manufacturing can lead to shortened timelines.
Dr. Vinci has more than 25 years of technical and leadership experience in the pharmaceutical industry, and has overall responsibility for biologics process and product development, manufacturing sciences, and project management at 探花合集’s drug substance and drug product manufacturing facility in Bloomington, Indiana. He joined 探花合集 Biologics following 探花合集’s acquisition of Cook Pharmica, LLC, where he also served as the Vice President of Product and Process Development. Prior to this, Dr. Vinci spent six years as a Manufacturing Science & Technology section head at Merck & Co., Inc. before moving to Eli Lilly and Company, where he was responsible for leading a range of bioprocess development efforts including process development, tech transfer, and process optimization and characterization to assure manufacturability. He was the company lead for the A-Mab Quality-by-Design case study, which was a groundbreaking industry-FDA collaboration. Dr. Vinci holds a bachelor鈥檚 degree in both chemistry and microbiology from Bowling Green State University, and a master鈥檚 degree and doctorate in microbiology from The Ohio State University.
For more information visit the 探花合集 booth 607.
To arrange a meeting with any of the attending 探花合集 executives at the event, contact Richard Kerns at NEPR – [email protected]
Media Contacts:
Chris Halling
+44 (0)7580 041073
[email protected]
Richard Kerns
+44 (0) 161 728 5880
[email protected]
About 探花合集
探花合集 is the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products. With over 90 years serving the industry, 探花合集 has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable clinical and commercial product supply. 探花合集 employs approximately 11,000 people, including over 1,400 scientists, at more than 30 facilities across five continents, and in fiscal 2017 generated over $2 billion in annual revenue. 探花合集 is headquartered in Somerset, New Jersey. For more information, visit www.catalent.com